Trial reportBMC infectious diseases2026
Continuous versus intermittent vancomycin infusions in critically ill children with gram-positive bacterial infections: a randomized controlled trial.
Trial report in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vancomycin exposure in critically ill children undergoing high intensity continuous renal replacement therapy.Pediatric nephrology (Berlin, Germany) · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis randomized controlled trial (RCT) compares continuous intravenous infusion (CIV) and intermittent infusion of vancomycin (IIV) regimens (40 mg/kg/day) in PICU patients with Gram-positive infections. The study aims to evaluate pharmacokinetics/pharmacodynamics (PK/PD) target attainment (Area under curve/Minimum inhibitory concentration, AUC/MIC ≥ 400) and renal safety profiles, with the ultimate goal of establishing optimized dosing protocols to enhance first-dose attainment of steady-state concentrations and enhance AUC/MIC ratio compliance, thereby supporting individualized treatment strategies for critically ill children.
methodsThis single-center RCT was conducted at the PICU of Capital Center for Children’s Health, Capital Medical University (a tertiary pediatric critical care center specializing in severe infections in critically ill children) from June 2017 to June 2020. Eighty children (1 month to 14 years) with suspected or confirmed Gram-positive infections requiring vancomycin were randomized 1:1 to CIV (n = 40; 24-hour continuous infusion) or IIV (n = 40; intermittent infusion every 6 h, 1-hour infusion each time). PK/PD parameters (AUC0–24 h/MIC), clinical outcomes, and renal adverse events were compared.
resultsCIV achieved higher steady-state vancomycin concentrations than IIV (15.22 mg/L vs. 6.25 mg/L, p < 0.05). AUC0–24 h/MIC values were numerically higher in CIV (median 456.5 [Interquartile Range, IQR 291.9-590.9]) versus IIV (median 358.0 [IQR 276.1-714.4]), though differences were non-significant (p > 0.05).Between-group differences in clinical efficacy, including fever resolution and inflammatory markers, were not observed (p > 0.05).
conclusionCIV rapidly achieves target vancomycin exposure in critically ill children without dose escalation, demonstrating comparable efficacy and renal safety to IIV. This strategy may optimize antimicrobial therapy in pediatric sepsis.
trial registrationThis trial was registered at the Chinese Clinical Trial Registry (ChiCTR) on 24 February 2021 with the registration number ChiCTR2100043659
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.